Cargando…
Oncolytic H-1 Parvovirus Hijacks Galectin-1 to Enter Cancer Cells
Clinical studies in glioblastoma and pancreatic carcinoma patients strongly support the further development of H-1 protoparvovirus (H-1PV)-based anticancer therapies. The identification of cellular factors involved in the H-1PV life cycle may provide the knowledge to improve H-1PV anticancer potenti...
Autores principales: | Ferreira, Tiago, Kulkarni, Amit, Bretscher, Clemens, Nazarov, Petr V., Hossain, Jubayer A., Ystaas, Lars A. R., Miletic, Hrvoje, Röth, Ralph, Niesler, Beate, Marchini, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146882/ https://www.ncbi.nlm.nih.gov/pubmed/35632759 http://dx.doi.org/10.3390/v14051018 |
Ejemplares similares
-
Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry
por: Kulkarni, Amit, et al.
Publicado: (2021) -
Oncolytic H-1 Parvovirus Enters Cancer Cells through Clathrin-Mediated Endocytosis
por: Ferreira, Tiago, et al.
Publicado: (2020) -
H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future
por: Bretscher, Clemens, et al.
Publicado: (2019) -
Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects
por: Hossain, Jubayer A, et al.
Publicado: (2020) -
Oncolytic parvoviruses: from basic virology to clinical applications
por: Marchini, Antonio, et al.
Publicado: (2015)